Full Press Release Details
| For investors | For media | |
| +1 858-221-3304 | +1 619-510-1281 | |
| investorrelations@resmed.com | news@resmed.com |
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, April 30, 2026 - Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.
"Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined
execution of our strategy," said Resmed's Chairman and CEO, Mick Farrell.
"Year-over-year, we delivered 11% reported revenue growth, 290 basis
points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of
sleep health, breathing health, and healthcare in the home.
As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to
care globally, scaling our digital health capabilities, and delivering further strong, profitable growth."
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
| Three Months Ended | ||||||||||||||||
| March 31, 2026 | March 31, 2025 | % Change | Constant Currency (A) | |||||||||||||
| Revenue | $ | 1,431.4 | $ | 1,291.7 | 11 | % | 8 | % | ||||||||
| Gross margin | 62.2 | % | 59.3 | % | 5 | |||||||||||
| Non-GAAP gross margin (B) | 62.8 | % | 59.9 | % | 5 | |||||||||||
| Selling, general, and administrative expenses | 285.7 | 245.3 | 16 | 11 | ||||||||||||
| Non-GAAP selling, general, and administrative expenses (B) | 279.8 | 245.3 | 14 | 9 | ||||||||||||
| Research and development expenses | 94.3 | 83.9 | 12 | 8 | ||||||||||||
| Income from operations | 499.8 | 426.3 | 17 | |||||||||||||
| Non-GAAP income from operations (B) | 524.8 | 444.6 | 18 | |||||||||||||
| Net income | 398.7 | 365.0 | 9 | |||||||||||||
| Non-GAAP net income (B) | 417.2 | 348.5 | 20 | |||||||||||||
| Diluted earnings per share | $ | 2.74 | $ | 2.48 | 10 | |||||||||||
| Non-GAAP diluted earnings per share (B) | $ | 2.86 | $ | 2.37 | 21 |
| Nine Months Ended | ||||||||||||||||
| March 31, 2026 | March 31, 2025 | % Change | Constant Currency (A) | |||||||||||||
| Revenue | $ | 4,189.8 | $ | 3,798.3 | 10 | % | 8 | % | ||||||||
| Gross margin | 61.8 | % | 58.8 | % | 5 | |||||||||||
| Non-GAAP gross margin (B) | 62.4 | % | 59.4 | % | 5 | |||||||||||
| Selling, general, and administrative expenses | 823.2 | 725.9 | 13 | 10 | ||||||||||||
| Non-GAAP selling, general, and administrative expenses (B) | 817.4 | 725.9 | 13 | 9 | ||||||||||||
| Research and development expenses | 272.6 | 244.8 | 11 | 9 | ||||||||||||
| Income from operations | 1,438.0 | 1,230.8 | 17 | |||||||||||||
| Non-GAAP income from operations (B) | 1,524.1 | 1,286.9 | 18 | |||||||||||||
| Net income | 1,139.9 | 1,021.0 | 12 | |||||||||||||
| Non-GAAP net income (B) | 1,203.5 | 1,032.2 | 17 | |||||||||||||
| Diluted earnings per share | $ | 7.79 | $ | 6.93 | 12 | |||||||||||
| Non-GAAP diluted earnings per share (B) | $ | 8.22 | $ | 7.00 | 17 |
Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted
Other Business and Operational Highlights
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed's
common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ("CDIs") trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the
record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from
the ASX's settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive.
Resmed will discuss its third quarter fiscal year
2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed's Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon
for the "Q3 2026 Earnings Webcast" to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone
replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or
+1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.
Resmed (NYSE: RMD, ASX: RMD) creates life-changing
health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered
digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better
sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the
Private Securities Litigation Reform Act of 1995. These forward-looking statements - including statements regarding Resmed's projections of future revenue or earnings, expenses, new product development, new product launches, new markets
for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business - are subject to risks and
uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed's periodic reports on file with the U.S.
Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
thousands, except for per share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| Net revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | ||||||||
| Cost of sales | 532,577 | 517,883 | 1,575,796 | 1,540,684 | ||||||||||||
| Amortization of acquired intangibles (1) | 7,850 | 7,444 | 23,480 | 22,748 | ||||||||||||
| Total cost of sales | $ | 540,427 | $ | 525,327 | $ | 1,599,276 | $ | 1,563,432 | ||||||||
| Gross profit | $ | 890,979 | $ | 766,409 | $ | 2,590,520 | $ | 2,234,902 | ||||||||
| Selling, general, and administrative | 279,797 | 245,302 | 817,387 | 725,894 | ||||||||||||
| Acquisition and portfolio review related expenses (1) | 5,858 | - | 5,858 | - | ||||||||||||
| Total selling, general, and administrative | 285,655 | 245,302 | 823,245 | 725,894 | ||||||||||||
| Research and development | 94,267 | 83,944 | 272,560 | 244,840 | ||||||||||||
| Amortization of acquired intangibles (1) | 11,247 | 10,895 | 34,967 | 33,345 | ||||||||||||
| Restructuring expenses (1) | - | - | 21,745 | - | ||||||||||||
| Total operating expenses | $ | 391,169 | $ | 340,141 | $ | 1,152,517 | $ | 1,004,079 | ||||||||
| Income from operations | $ | 499,810 | $ | 426,268 | $ | 1,438,003 | $ | 1,230,823 | ||||||||
| Other income (expenses), net: | ||||||||||||||||
| Interest (expense) income, net | $ | 12,287 | $ | 793 | $ | 29,029 | $ | (1,643 | ) | |||||||
| Gain (loss) attributable to equity method investments | 1,718 | 335 | 4,722 | 2,375 | ||||||||||||
| Gain (loss) on equity investments | (10,130 | ) | (5,647 | ) | (16,014 | ) | (7,765 | ) | ||||||||
| Other, net | (1,373 | ) | (4,056 | ) | (10,488 | ) | (4,277 | ) | ||||||||
| Total other income (expenses), net | 2,502 | (8,575 | ) | 7,249 | (11,310 | ) | ||||||||||
| Income before income taxes | $ | 502,312 | $ | 417,693 | $ | 1,445,252 | $ | 1,219,513 | ||||||||
| Income taxes | 103,580 | 52,652 | 305,391 | 198,495 | ||||||||||||
| Net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | ||||||||
| Basic earnings per share | $ | 2.74 | $ | 2.49 | $ | 7.82 | $ | 6.96 | ||||||||
| Diluted earnings per share | $ | 2.74 | $ | 2.48 | $ | 7.79 | $ | 6.93 | ||||||||
| Non-GAAP diluted earnings per share (1) | $ | 2.86 | $ | 2.37 | $ | 8.22 | $ | 7.00 | ||||||||
| Basic shares outstanding | 145,340 | 146,719 | 145,794 | 146,797 | ||||||||||||
| Diluted shares outstanding | 145,723 | 147,220 | 146,369 | 147,432 |
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
| March 31, 2026 | June 30, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,660,513 | $ | 1,209,450 | ||||
| Accounts receivable, net | 998,837 | 939,492 | ||||||
| Inventories | 911,876 | 927,711 | ||||||
| Prepayments and other current assets | 492,836 | 428,952 | ||||||
| Total current assets | $ | 4,064,062 | $ | 3,505,605 | ||||
| Non-current assets: | ||||||||
| Property, plant, and equipment, net | $ | 566,972 | $ | 550,790 | ||||
| Operating lease right-of-use assets | 161,602 | 167,497 | ||||||
| Goodwill and other intangibles, net | 3,468,321 | 3,511,541 | ||||||
| Deferred income taxes and other non-current assets | 523,328 | 438,958 | ||||||
| Total non-current assets | $ | 4,720,223 | $ | 4,668,786 | ||||
| Total assets | $ | 8,784,285 | $ | 8,174,391 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 273,301 | $ | 278,157 | ||||
| Accrued expenses | 446,149 | 402,253 | ||||||
| Operating lease liabilities, current | 29,233 | 30,506 | ||||||
| Deferred revenue | 179,277 | 166,030 | ||||||
| Income taxes payable | 163,322 | 132,274 | ||||||
| Short-term debt | 259,928 | 9,900 | ||||||
| Total current liabilities | $ | 1,351,210 | $ | 1,019,120 | ||||
| Non-current liabilities: | ||||||||
| Deferred revenue | $ | 163,148 | $ | 156,803 | ||||
| Deferred income taxes | 77,929 | 77,682 | ||||||
| Operating lease liabilities, non-current | 149,840 | 153,015 | ||||||
| Other long-term liabilities | 146,079 | 141,520 | ||||||
| Long-term debt | 404,168 | 658,392 | ||||||
| Total non-current liabilities | $ | 941,164 | $ | 1,187,412 | ||||
| Total liabilities | $ | 2,292,374 | $ | 2,206,532 | ||||
| Stockholders' equity | ||||||||
| Common stock | $ | 763 | $ | 761 | ||||
| Additional paid-in capital | 2,134,231 | 2,033,599 | ||||||
| Retained earnings | 6,958,779 | 6,081,490 | ||||||
| Treasury stock | (2,576,957 | ) | (2,073,292 | ) | ||||
| Accumulated other comprehensive income | (24,905 | ) | (74,699 | ) | ||||
| Total stockholders' equity | $ | 6,491,911 | $ | 5,967,859 | ||||
| Total liabilities and stockholders' equity | $ | 8,784,285 | $ | 8,174,391 |
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | ||||||||
| Adjustment to reconcile net income to cash provided by operating activities: | ||||||||||||||||
| Depreciation and amortization | 58,981 | 43,675 | 156,564 | 134,845 | ||||||||||||
| Amortization of right-of-use assets | 10,051 | 8,235 | 32,467 | 26,678 | ||||||||||||
| Stock-based compensation costs | 26,792 | 24,120 | 76,890 | 66,910 | ||||||||||||
| (Gain) loss attributable to equity method investments, net of dividends received | (1,718 | ) | (335 | ) | (4,722 | ) | (2,375 | ) | ||||||||
| (Gain) loss on equity investments | 10,130 | 5,647 | 16,014 | 7,765 | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable, net | (16,857 | ) | (40,033 | ) | (59,569 | ) | (71,469 | ) | ||||||||
| Inventories, net | 12,480 | 29,864 | 23,946 | (48,032 | ) | |||||||||||
| Prepaid expenses, net deferred income taxes and other current assets | (48,335 | ) | 79,357 | (152,410 | ) | 35,612 | ||||||||||
| Accounts payable, accrued expenses, income taxes payable and other | 103,876 | 63,091 | 122,157 | 41,870 | ||||||||||||
| Net cash provided by (used in) operating activities | $ | 554,132 | $ | 578,662 | $ | 1,351,198 | $ | 1,212,822 | ||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Purchases of property, plant, and equipment | (33,654 | ) | (20,796 | ) | (105,158 | ) | (59,280 | ) | ||||||||
| Patent registration and acquisition costs | (5,935 | ) | (2,992 | ) | (13,286 | ) | (7,584 | ) | ||||||||
| Purchases of intangible assets | - | - | (1,479 | ) | - | |||||||||||
| Business acquisitions, net of cash acquired | (24,883 | ) | - | (25,405 | ) | (670 | ) | |||||||||
| Purchases of investments | (20,132 | ) | (2,053 | ) | (26,536 | ) | (4,403 | ) | ||||||||
| Proceeds from exits of investments | 2,502 | - | 2,752 | 4,378 | ||||||||||||
| Proceeds (payments) on maturity of foreign currency contracts | 24,074 | (5,945 | ) | 7,564 | 1,227 | |||||||||||
| Net cash provided by (used in) investing activities | $ | (58,028 | ) | $ | (31,786 | ) | $ | (161,548 | ) | $ | (66,332 | ) | ||||
| Cash flows from financing activities: | ||||||||||||||||
| Proceeds from issuance of common stock, net | 7,427 | 9,022 | 45,189 | 44,283 | ||||||||||||
| Purchases of treasury stock | (175,013 | ) | (75,026 | ) | (500,037 | ) | (200,017 | ) | ||||||||
| Taxes paid related to net share settlement of equity awards | (418 | ) | (364 | ) | (21,445 | ) | (17,487 | ) | ||||||||
| Payments of business combination contingent consideration | - | - | - | (855 | ) | |||||||||||
| Repayment of borrowings | - | - | (5,000 | ) | (35,000 | ) | ||||||||||
| Dividends paid | (87,238 | ) | (77,704 | ) | (262,572 | ) | (233,290 | ) | ||||||||
| Net cash provided by (used in) financing activities | $ | (255,242 | ) | $ | (144,072 | ) | $ | (743,865 | ) | $ | (442,366 | ) | ||||
| Effect of exchange rate changes on cash | $ | 2,582 | $ | 7,963 | $ | 5,278 | $ | (9,774 | ) | |||||||
| Net increase (decrease) in cash and cash equivalents | 243,444 | 410,767 | 451,063 | 694,350 | ||||||||||||
| Cash and cash equivalents at beginning of period | 1,417,069 | 521,944 | 1,209,450 | 238,361 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 1,660,513 | $ | 932,711 | $ | 1,660,513 | $ | 932,711 |
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures "non-GAAP gross profit" and "non-GAAP gross margin" exclude amortization expense from acquired intangibles and are
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| Revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | ||||||||
| GAAP cost of sales | $ | 540,427 | $ | 525,327 | $ | 1,599,276 | $ | 1,563,432 | ||||||||
| Less: Amortization of acquired intangibles (A) | (7,850 | ) | (7,444 | ) | (23,480 | ) | (22,748 | ) | ||||||||
| Non-GAAP cost of sales | $ | 532,577 | $ | 517,883 | $ | 1,575,796 | $ | 1,540,684 | ||||||||
| GAAP gross profit | $ | 890,979 | $ | 766,409 | $ | 2,590,520 | $ | 2,234,902 | ||||||||
| GAAP gross margin | 62.2 | % | 59.3 | % | 61.8 | % | 58.8 | % | ||||||||
| Non-GAAP gross profit | $ | 898,829 | $ | 773,853 | $ | 2,614,000 | $ | 2,257,650 | ||||||||
| Non-GAAP gross margin | 62.8 | % | 59.9 | % | 62.4 | % | 59.4 | % |
The measures "non-GAAP selling, general, and administrative expenses" and "non-GAAP selling, general, and administrative expenses as a percentage of revenues" exclude acquisition and portfolio review related expenses and are reconciled below:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| Revenue | $ | 1,431,406 | $ | 1,291,736 | $ | 4,189,796 | $ | 3,798,334 | ||||||||
| GAAP selling, general, and administrative | 285,655 | 245,302 | 823,245 | 725,894 | ||||||||||||
| Less: Acquisition and portfolio review related expenses (A) | (5,858 | ) | - | (5,858 | ) | - | ||||||||||
| Non-GAAP selling, general, and administrative | 279,797 | 245,302 | 817,387 | 725,894 | ||||||||||||
| As a percentage of revenue: | ||||||||||||||||
| GAAP selling, general, and administrative expenses | 20.0 | % | 19.0 | % | 19.6 | % | 19.1 | % | ||||||||
| Non-GAAP selling, general, and administrative expenses | 19.5 | % | 19.0 | % | 19.5 | % | 19.1 | % |
The measure "non-GAAP income from operations" is reconciled with GAAP
income from operations below:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| GAAP income from operations | $ | 499,810 | $ | 426,268 | $ | 1,438,003 | $ | 1,230,823 | ||||||||
| Amortization of acquired intangibles-cost of sales (A) | 7,850 | 7,444 | 23,480 | 22,748 | ||||||||||||
| Amortization of acquired intangibles-operating expenses (A ) | 11,247 | 10,895 | 34,967 | 33,345 | ||||||||||||
| Restructuring (A) | - | - | 21,745 | - | ||||||||||||
| Acquisition and portfolio review related expenses (A ) | 5,858 | - | 5,858 | - | ||||||||||||
| Non-GAAP income from operations | $ | 524,765 | $ | 444,607 | $ | 1,524,053 | $ | 1,286,916 |
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted
earnings per share in the table below:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, 2026 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||
| GAAP net income | $ | 398,732 | $ | 365,041 | $ | 1,139,861 | $ | 1,021,018 | ||||||||
| Amortization of acquired intangibles-cost of sales (A) | 7,850 | 7,444 | 23,480 | 22,748 | ||||||||||||
| Amortization of acquired intangibles-operating expenses (A) | 11,247 | 10,895 | 34,967 | 33,345 | ||||||||||||
| Restructuring expenses (A) | - | - | 21,745 | - | ||||||||||||
| Acquisition and portfolio review related expenses (A) | 5,858 | - | 5,858 | - | ||||||||||||
| Income tax effect of interest and penalties on income tax refunds (A) | - | (29,976 | ) | - | (29,976 | ) | ||||||||||
| Income tax effect on non-GAAP adjustments (A) | (6,519 | ) | (4,871 | ) | (22,394 | ) | (14,904 | ) | ||||||||
| Non-GAAP net income (A) | $ | 417,168 | $ | 348,533 | $ | 1,203,517 | $ | 1,032,231 | ||||||||
| GAAP diluted shares outstanding | 145,723 | 147,220 | 146,369 | 147,432 | ||||||||||||
| GAAP diluted earnings per share | $ | 2.74 | $ | 2.48 | $ | 7.79 | $ | 6.93 | ||||||||
| Non-GAAP diluted earnings per share (A) | $ | 2.86 | $ | 2.37 | $ | 8.22 | $ | 7.00 |
Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that
investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current
period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like
all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under
RMD Third Quarter 2026 Earnings Press Release - April 30, 2026
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
(Unaudited; $ in millions, except for per
| Three Months Ended | ||||||||||||||||||||||||
| March 31, 2026 | (A) | March 31, 2025 | (A) | % Change | Constant Currency (B) | |||||||||||||||||||
| U.S., Canada, and Latin America | ||||||||||||||||||||||||
| Devices | $ | 447.5 | $ | 422.7 | 6 | % | ||||||||||||||||||
| Masks and other | 371.2 | 326.7 | 14 | |||||||||||||||||||||
| Total U.S., Canada and Latin America | $ | 818.7 | $ | 749.3 | 9 | |||||||||||||||||||
| Combined Europe, Asia, and other markets | ||||||||||||||||||||||||
| Devices | $ | 288.2 | $ | 253.5 | 14 | % | 6 | % | ||||||||||||||||
| Masks and other | 153.6 | 127.7 | 20 | 10 | ||||||||||||||||||||
| Total Combined Europe, Asia and other markets | $ | 441.8 | $ | 381.3 | 16 | 7 | ||||||||||||||||||
| Global revenue | ||||||||||||||||||||||||
| Total Devices | $ | 735.7 | $ | 676.2 | 9 | % | 6 | % | ||||||||||||||||
| Total Masks and other | 524.8 | 454.4 | 15 | 12 | ||||||||||||||||||||
| Total Sleep and Breathing Health | $ | 1,260.5 | $ | 1,130.6 | 11 | 8 | ||||||||||||||||||
| Residential Care Software | 170.9 | 161.2 | 6 | 4 | ||||||||||||||||||||
| Total | $ | 1,431.4 | $ | 1,291.7 | 11 | 8 |
| Nine Months Ended | ||||||||||||||||||||||||
| March 31, 2026 | (A) | March 31, 2025 | (A) | % Change | Constant Currency (B) | |||||||||||||||||||
| U.S., Canada, and Latin America | ||||||||||||||||||||||||
| Devices | $ | 1,309.0 | $ | 1,221.6 | 7 | % | ||||||||||||||||||
| Masks and other | 1,119.5 | 983.9 | 14 | |||||||||||||||||||||
| Total U.S., Canada and Latin America | $ | 2,428.5 | $ | 2,205.6 | 10 | |||||||||||||||||||
| Combined Europe, Asia, and other markets | ||||||||||||||||||||||||
| Devices | $ | 833.3 | $ | 749.6 | 11 | % | 6 | % | ||||||||||||||||
| Masks and other | 424.2 | 368.7 | 15 | 7 | ||||||||||||||||||||
| Total Combined Europe, Asia and other markets | $ | 1,257.4 | $ | 1,118.3 | 12 | 6 | ||||||||||||||||||
| Global revenue | ||||||||||||||||||||||||
| Total Devices | $ | 2,142.3 | $ | 1,971.3 | 9 | % | 7 | % | ||||||||||||||||
| Total Masks and other | 1,543.6 | 1,352.6 | 14 | 12 | ||||||||||||||||||||
| Total Sleep and Breathing Health | $ | 3,685.9 | $ | 3,323.9 | 11 | 9 | ||||||||||||||||||
| Residential Care Software | 503.9 | 474.4 | 6 | 4 | ||||||||||||||||||||
| Total | $ | 4,189.8 | $ | 3,798.3 | 10 | 8 |